The global antinuclear antibody (ANA) testing market is segmented based on products, diseases, techniques, end users, and regions. The assay kits& reagents segment is expected to register the highest growth rate in the antinuclear antibody (ANA) testing market, by product, during the forecast period. The high growth in this segment is attributed to the growing number of reagent rental agreements and increasing prevalence of autoimmune diseases worldwide. —
Complete report on antinuclear antibody (ANA) testing market spread across 166 pages, profiling 10 companies and supported with 73 tables and 102 figures is now available at http://www.rnrmarketresearch.com/antinuclear-antibody-test-market-by-product-reagents-assay-kits-systems-software-services-technique-immunofluorescence-elisa-multiplex-disease-rheumatoid-arthritis-sle-end-user-clinical-labs-hospi-st-to-2021-market-report.html .
Based on end users, the antinuclear antibody (ANA) testing market is segmented into clinical laboratories, hospitals, POLs, and other end users. The hospitals segment is expected to account for the largest share of the market in 2016. Increasing prevalence of autoimmune diseases, coupled with the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories, will be the major factors driving the growth of this market.
North America is the largest regional segment in the global antinuclear antibody (ANA) testing market, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American market is primarily driven by the rising geriatric population and the growing number of people covered under medical insurance in the U.S.
In addition to comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. The company profiles in this report comprise the product portfolios, developments, and strategies adopted by players to maintain and increase their shares in antinuclear antibody (ANA) testing market. The above mentioned market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach and levels of output in order to remain successful in the antinuclear antibody (ANA) testing market.
The major players in antinuclear antibody (ANA) testing market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.). Get a sample copy of this research at http://www.rnrmarketresearch.com/contacts/request-sample?rname=696521 .
Objectives of the Study:
> To define, describe, and forecast the global antinuclear antibody testing market on the basis of product, technique, disease, and end user
> To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and trends)
> To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
> To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
> To strategically analyze the market structure and profile the key players operating in the global ANA testing market and comprehensively analyze their core competencies
> To track and analyze competitive developments such as new product launches, agreements, expansions, and acquisitions in the global antinuclear antibody (ANA) testing market
On a related note, another research on North American Nuclear Medicine/Radiopharmaceuticals Market by Type, Therapeutic and by Application say, the market is poised to reach USD 2.98 billion by 2020 from USD 1.97 billion in 2015, growing at a CAGR of 8.6% during the forecast period of 2015 to 2020. The diagnostic radioisotopes segment is expected to account for the largest share of the North American nuclear medicine market in 2015. The SPECT applications segment is expected to account for the largest share of the North American nuclear medicine market in 2015. Increasing preference for SPECT and PET scans, alpha radio immunotherapy-based targeted cancer treatment, advances in radiotracers, growing incidence of cancer and CVDs, and rising awareness about the effective use of radiopharmaceuticals can be the major growth factors. Companies like Cardinal Health Inc., Mallinckrodt plc, GE Healthcare, Lantheus Medical Imaging, Inc., Bayer Healthcare, Bracco Imaging S.p.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Advanced Accelerator Applications S.A. and IBA Molecular Imaging have been profiled in this 180 pages research report available at http://www.rnrmarketresearch.com/north-american-nuclear-medicineradiopharmaceuticals-stable-isotopes-market-spectpet-radioisotopes-technetium-f-18-betaalpha-radiation-therapy-i131-y-90-applications-canceroncology-market-report.html .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets.
Name: Ritesh Tiwari
Email: Send Email
Organization: RnR Market Research
Address: 2nd Floor, Metropole, Next to Inox Theatre, Bund Garden Road, Pune - 411001 Maharashtra, India.
Release ID: 133952